Table 1 Tumor response criteria — WHO, RECIST 1.0 and RECIST 1.1 and classification of tumor assessment
WHO | RECIST 1.0 | RECIST 1.1 |
|---|---|---|
No particular number of lesions specified | Requires 10 targets per five organs when measuring the tumor burden | Requires only five targets (two per organ). |
Bi dimensionally measurable lesion; no stipulation of minimal size of the lesion | Measures the long axis of lymph nodes as for other lesions | Measures the short axis of lymph nodes and long axis for other lesions |
50% decrease in target lesions, without a 25% increase in any one target lesion; confirmed at 4 wk | Defines progression as a 20% increase in sum | A 20% increase and at least 5 mm absolute increase. |
States that disease progression for non-measurable disease “must be unequivocal” | Expands that definition to convey an impact on the overall burden of disease. | |
States that confirmation is required but in new version only if response is primary endpoint | Includes a new section that incorporates a comment on FDG PET interpretation |